Europe Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
Europe leber congential amaurosis market is projected to register a CAGR of 5.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
Market Segmentation
Europe Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Europe leber congential amaurosis market are:
• Genetic advances in the diagnosis of LCA
• Rising chronic disease
Market Players
The key market players for Europe leber congential amaurosis market are listed below:
• Invitae Corporation
• Spark Therapeutics, Inc.
• CENTOGENE N.V.
• Allergan
• CENTOGENE N.V.
• Novartis AG
Company Profiles
• Invitae Corporation
• Spark Therapeutics, Inc.
• CENTOGENE N.V.
• Allergan
• CENTOGENE N.V.
• Novartis AG
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook